Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents (Note 7)	$ 1,699.0	$ 2,337.5
Short-term investments (Note 7)	78.4	101.0
Accounts receivable, net of allowances of $23.7 (2020) and $22.4 (2019)	5,106.1	4,547.3
Other receivables	1,246.4	994.2
Inventories	3,102.4	3,190.7
Prepaid expenses and other	2,761.9	2,538.9
Total current assets	13,994.2	13,709.6
Investments (Note 7)	2,148.7	1,962.4
Goodwill	3,779.1	3,679.4
Other intangibles, net	7,766.7	6,618.0
Deferred tax assets	2,471.6	2,572.6
Property and equipment, net of accumulated depreciation of $9,141.5 (2020) and $9,161.6 (2019)	7,897.9	7,872.9
Other noncurrent assets	3,044.6	2,871.2
Total assets	41,102.8	39,286.1
Current Liabilities
Short-term borrowings and current maturities of long-term debt	3,248.0	1,499.3
Accounts payable	1,207.7	1,405.3
Employee compensation	565.8	915.5
Sales rebates and discounts	4,703.9	4,933.6
Dividends payable	0.0	671.5
Income taxes payable	667.4	160.6
Other current liabilities	2,217.4	2,189.4
Total current liabilities	12,610.2	11,775.2
Other Liabilities
Long-term debt	13,982.3	13,817.9
Accrued retirement benefits (Note 9)	3,632.0	3,698.2
Long-term income taxes payable	3,621.9	3,607.2
Deferred tax liabilities	2,186.2	2,187.5
Other noncurrent liabilities	1,873.0	1,501.0
Total other liabilities	25,295.4	24,811.8
Commitments and Contingencies (Note 10)
Eli Lilly and Company Shareholders’ Equity
Common stock	598.1	598.8
Additional paid-in capital	6,556.1	6,685.3
Retained earnings	5,879.4	4,920.4
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss (Note 11)	(6,885.9)	(6,523.6)
Cost of common stock in treasury	(55.7)	(60.8)
Total Eli Lilly and Company shareholders’ equity	3,078.8	2,606.9
Noncontrolling interests	118.4	92.2
Total equity	3,197.2	2,699.1
Total liabilities and equity	$ 41,102.8	$ 39,286.1